Humana (HUM) Ups '23 Medicare Advantage Membership Growth View

Humana Inc. HUM recently raised its membership growth outlook for 2023. A better-than-expected sales witnessed so far in the current enrollment period and modestly favorable retention are expected to support the growth.

The company hiked its 2023 individual Medicare Advantage membership growth guidance to a minimum of 500,000 members, up from the earlier increased estimated range of 325,000-400,000 members. Previously, HUM provided individual Medicare Advantage membership growth guidance of 150,000-200,000 members during 2022.

It expects 2023 net membership gains to be a minimum of 10.9% from the 2022 projection. HUM expects the industry growth rate to be in the high single digits. However, the membership growth is not expected to impact its 2023 adjusted EPS, which is estimated to grow 11-15% from the 2022 adjusted EPS guidance of $25.

The adjusted EPS guidance of 2022 includes transaction and integration costs of 62 cents per share and amortization of identifiable intangibles of 48 cents per share. The Zacks Consensus Estimate for 2022 and 2023 adjusted EPS are pegged at $25.05 and $27.97, respectively. Further, the consensus marks for 2022 and 2023 top lines indicate 11.7% and 9.3% year-over-year growth, respectively.

Humana managed to beat earnings estimates in each of the past four quarters, with an average of 10.4%.

Price Performance

Humana’s shares have improved 30.1% in the past year compared with the 23.9% rise of the industry it belongs to.

Zacks Investment Research
Image Source: Zacks Investment Research

Zacks Rank & Key Picks

Humana currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Elevance Health Inc. ELV, AMN Healthcare Services, Inc. AMN and Inventiva S.A. IVA, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for Elevance Health’s full-year earnings is currently pegged at $29.02 per share, indicating a year-over-year increase of 11.7%. ELV beat earnings estimates in all the past four quarters, with an average surprise of 4.1%.

The Zacks Consensus Estimate for AMN Healthcare’s current year bottom line indicates a 44% improvement from the prior-year reported number. The consensus estimate for AMN’s top line also indicates 30.1% year-over-year growth.

The Zacks Consensus Estimate for Inventiva’s 2022 bottom line indicates an 11.3% year-over-year improvement. IVA has witnessed one upward estimate revision in the past 60 days against none in the opposite direction.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Humana Inc. (HUM) : Free Stock Analysis Report

AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report

Inventiva S.A. Sponsored ADR (IVA) : Free Stock Analysis Report

Elevance Health, Inc. (ELV) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.